The open-label phase I clinical trial NCT04004637 enrolled patients with r/r CD7-positive T-cell acute lymphoblastic leukemia/lymphoma who underwent transfusion of autologous CD7-targeted CAR-T cells. This evidence concerns the gene CD7 and lymphoma.